Showing results (121-130 of 133) with videos related to
Sort By:
Pageof 14
Breast Cancer Research and Treatment|August 2, 2020
Impact of breast cancer subtype on clinical outcomes after Gamma Knife radiosurgery for brain metastases from breast cancer: a multi-institutional retrospective study (JLGK1702)Kyoko Aoyagi, Yoshinori Higuchi, Shigeo Matsunaga, et al.Heliyon|September 9, 2020
Elevated levels of autoantibodies against DNAJC2 in sera of patients with atherosclerotic diseasesYoichi Yoshida, Xiao-Meng Zhang, Hao Wang, et al.International Journal of Molecular Medicine|September 18, 2020
Association between serum anti‑ASXL2 antibody levels and acute ischemic stroke, acute myocardial infarction, diabetes mellitus, chronic kidney disease and digestive organ cancer, and their possible association with atherosclerosis and hypertensionShu-Yang Li, Yoichi Yoshida, Eiichi Kobayashi, et al.Frontiers in Cardiovascular Medicine|February 27, 2023
Utility of atherosclerosis-associated serum antibodies against colony-stimulating factor 2 in predicting the onset of acute ischemic stroke and prognosis of colorectal cancerShu-Yang Li, Yoichi Yoshida, Masaaki Kubota, et al.BMC Neurology|July 10, 2021
Association of serum levels of antibodies against ALDOA and FH4 with transient ischemic attack and cerebral infarctionHao Wang, Hao Lu, Xiao-Meng Zhang, et al.Communications Biology|November 26, 2022
Proteogenomic landscape and clinical characterization of GH-producing pituitary adenomas/somatotroph pituitary neuroendocrine tumorsAzusa Yamato, Hidekazu Nagano, Yue Gao, et al.Scientific Reports|June 30, 2021
Serum anti-AP3D1 antibodies are risk factors for acute ischemic stroke related with atherosclerosisShu-Yang Li, Yoichi Yoshida, Eiichi Kobayashi, et al.Cancer Science|September 17, 2020
Serum anti-LRPAP1 is a common biomarker for digestive organ cancers and atherosclerotic diseasesMakoto Sumazaki, Hideaki Shimada, Masaaki Ito, et al.Journal of Neuro-Oncology|March 21, 2018
JCOG0911 INTEGRA study: a randomized screening phase II trial of interferonβ plus temozolomide in comparison with temozolomide alone for newly diagnosed glioblastomaToshihiko Wakabayashi, Atsushi Natsume, Junki Mizusawa, et al.Oncotarget|February 22, 2018
Association of serum levels of antibodies against MMP1, CBX1, and CBX5 with transient ischemic attack and cerebral infarctionHao Wang, Xiao-Meng Zhang, Go Tomiyoshi, et al.Pageof 14